The KISIMA® technology is highly versatile and flexible with potential applications including therapeutic vaccines in oncology, but also in infectious diseases. KISIMA® can also be developed as a synthetic platform for the delivery of neo-antigens or modified epitopes.
Our strategy is to develop KISIMA® and its current indications in oncology (including metastatic colorectal cancer) through to phase II, in-house or through strategic partnerships.
ATP128, our first asset is anticipated to start phase I clinical trial in 2019. We would then consider out licensing it to advance our other undisclosed assets as well as explore additional indications.